Fundraising Fox

AvenCell

65 employees on LinkedIn · 7 known investors

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.

BiotechLongevityMedical Devices

Founders & leadership

AS
Andrew SchiermeierinChief Executive Officer

Investors · 7

Novo Holdings✓ verifiedCopenhagen · $1.1M – $54M
Blackstone Life Sciences✓ verifiedNew York · $20M – $60M
Eight Roads VenturesMumbai · $5M – $30M
F-Prime CapitalCambridge · $3M – $10M
NYBC VenturesNew York

Also in the syndicate · 2

Eight Roads Ventures JapanPiper Heartland Healthcare Capital

Funding

SEC filings, press & company announcements

$112M disclosed across 1 round · 2024

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 3

by search overlap
Agenus11 shared keywords
Applied StemCell10 shared keywordsLeading CRO/CDMO specializing in cell and gene therapy with proprietary TARGATT genome editing and iPSC platform
Anavex Life Sciences9 shared keywordsAnavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Its lead compound is ANAVEX 2-73 (blarcamesine), targeting early Alzheimer's and neurodevelopmental rare diseases.

Companies competing with AvenCell for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignanciesprnewswire.com · Apr 2026Cell Therapy Fundings (2025 YTD): Key Deals and Trendsbiopharmiq.com · Aug 2025AvenCell: Clinical-Stage Cell Therapy Company Raises $112 Million (Series B)pulse2.com · Nov 2024US: AvenCell Therapeutics raises US$112m in Series B financing - Investors in Healthcareinvestorsinhealthcare.com · Oct 2024AvenCell Raises $112M in Series B Fundingfinsmes.com · Oct 2024AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdingsprnewswire.com · Oct 2024

Frequently asked questions

What does AvenCell do?
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.
Who are AvenCell's investors?
AvenCell's investors include Novo Holdings, Blackstone Life Sciences, Eight Roads Ventures, F-Prime Capital, NYBC Ventures.
How much funding has AvenCell raised?
AvenCell has disclosed $112M raised across 1 round.